Literature DB >> 2448031

Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry.

H Baisch1, J Gerdes.   

Abstract

The antibody Ki-67, which detects proliferating cells, was used in combination with propidium iodide, a DNA-specific dye. The double-staining method allowed discrimination of cells in the phases of the cell cycle as well as the recognition of Ki-67 staining characteristics. Suspension cultures of U937 cells were measured in exponential growth and plateau phase in nutritional deprivation. The fraction of Ki-67 positive cells was nearly 100% 2 days after dilution and 46% 7 days after dilution of the cultures. Stathmokinetic measurements with colchicine and flow cytometry measurements with the BrdU-Hoechst technique yielded close to 100% proliferation at day 2 but only 18% and 6%, respectively, at day 7. The discrepancy between Ki-67 results and the results of the two other methods is considered to be a characteristic of nutritionally deprived cells.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2448031     DOI: 10.1111/j.1365-2184.1987.tb01323.x

Source DB:  PubMed          Journal:  Cell Tissue Kinet        ISSN: 0008-8730


  15 in total

Review 1.  Review: assessment of cell proliferation in histological material.

Authors:  P A Hall; D A Levison
Journal:  J Clin Pathol       Date:  1990-03       Impact factor: 3.411

2.  Expression of MIB-1, mitotic index and S-phase fraction as indicators of cell proliferation in superficial bladder cancer. Finnbladder Group.

Authors:  T J Liukkonen; P K Lipponen; M Helle; H K Haapasalo; S Nordling; P Rajala
Journal:  Urol Res       Date:  1996

3.  A comparative study of cell proliferation markers in breast carcinomas.

Authors:  A S Leong; S Vinyuvat; C Suthipintawong; J Milios
Journal:  Clin Mol Pathol       Date:  1995-04

4.  In vitro cytotoxicity of S16020-2, a new olivacine derivative.

Authors:  S Léonce; V Perez; M R Casabianca-Pignede; M Anstett; E Bisagni; A Pierré; G Atassi
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

5.  MCM-2 and MCM-5 expression in gastric adenocarcinoma: clinical significance and comparison with Ki-67 proliferative marker.

Authors:  Constantinos Giaginis; Athina Giagini; Gerasimos Tsourouflis; Elisavet Gatzidou; Emmanuel Agapitos; Gregorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2010-08-06       Impact factor: 3.199

Review 6.  The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications.

Authors:  C C Yu; A L Woods; D A Levison
Journal:  Histochem J       Date:  1992-03

7.  Expression of the proliferation-associated Ki-67 antigen of transferrin receptors and of DNA polymerase alpha in human tumour lines: implications for in vitro chemoresistance.

Authors:  T Licht; K J Bross; H H Fiebig; K Schötta; D P Berger; C Dreher; G W Löhr; F Herrmann
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

8.  Clinical significance of MCM-2 and MCM-5 expression in colon cancer: association with clinicopathological parameters and tumor proliferative capacity.

Authors:  Constantinos Giaginis; Maria Georgiadou; Konstantina Dimakopoulou; Gerasimos Tsourouflis; Elisavet Gatzidou; Gregorios Kouraklis; Stamatios Theocharis
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

9.  Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance.

Authors:  Naruo Tokuyasu; Kohei Shomori; Keisuke Nishihara; Hiroki Kawaguchi; Shinji Fujioka; Kensaku Yamaga; Masahide Ikeguchi; Hisao Ito
Journal:  Gastric Cancer       Date:  2008-03-29       Impact factor: 7.370

10.  Implication of cell kinetic changes during the progression of human prostatic cancer.

Authors:  R R Berges; J Vukanovic; J I Epstein; M CarMichel; L Cisek; D E Johnson; R W Veltri; P C Walsh; J T Isaacs
Journal:  Clin Cancer Res       Date:  1995-05       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.